End stage renal disease (ESRD). End stage renal disease
Conditions
Interventions
Intervention 1: Intervention group: Pearl Omega-3 1000 mg (Zahravi Pharmaceutical Company) daily for 3 weeks will be prescribed to the patients in the intervention group. The usage method will be eluc
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with End-stage renal disease undergoing regular hemodialysis
Exclusion criteria
Exclusion criteria: Age group under 18 Diagnosed with active infection Diagnosed with severe heart failure Bilaterally Injured cubital vascular anatomy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The numerical value of flow-mediated vasodilation which is calculated using sonography machine based on percentage. Timepoint: Calculation of flow-mediated vasodilation, once in the beginning of the study (baseline values before initiation of the treatment), and subsequently, three weeks following the continuation of Omega-3 supplementation. Method of measurement: The numerical number will be calculated using sonography machine. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Akhavi Milani
Tabriz University of Medical Sciences
Outcome results
None listed